Cirrhosis Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, ROA, and Companies by DelveInsight | NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, MORE

(Albany, USA) DelveInsight's, "Cirrhosis Pipeline Insight, 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Cirrhosis pipeline landscape. It covers the Cirrhosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Cirrhosis Pipeline Report
• DelveInsight's Cirrhosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Cirrhosis treatment.
• The leading companies working in the Cirrhosis Market include GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
• Promising Cirrhosis Pipeline Therapies in the various stages of development include NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
• On August 2023, Grifols Therapeutics LLC announced a study of Phase 3 Clinical Trials for Albutein 20% Injectable Solution. This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites.
• On September 2023, AstraZeneca announced a study of Phase 2 Clinical Trials for zibotentan (dose B) + dapagliflozin. This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.

Request a sample and discover the recent advances in Cirrhosis Treatment Drugs @ Cirrhosis Pipeline Report- https://www.delveinsight.com/report-store/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Cirrhosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Cirrhosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Cirrhosis clinical trial landscape.

Cirrhosis Overview
Cirrhosis is a late-stage liver disease characterized by extensive scarring (fibrosis) of liver tissue, which impairs its ability to function properly. It results from chronic liver damage caused by various conditions, including chronic alcohol abuse, hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), and autoimmune hepatitis. The healthy liver tissue is progressively replaced by scar tissue, obstructing blood flow through the liver and diminishing its essential functions, such as detoxifying harmful substances, producing blood-clotting proteins, and regulating nutrients.
Symptoms of cirrhosis often emerge gradually and can include fatigue, jaundice (yellowing of the skin and eyes), easy bruising, itching, swelling in the legs and abdomen (edema and ascites), and confusion due to the buildup of toxins in the blood (hepatic encephalopathy). Advanced cirrhosis can lead to life-threatening complications like portal hypertension, esophageal varices, and liver cancer.
Diagnosis involves a combination of medical history, physical examination, blood tests, imaging studies, and sometimes liver biopsy. Treatment focuses on managing symptoms, slowing disease progression, and addressing underlying causes. Lifestyle changes, such as abstaining from alcohol and following a healthy diet, are crucial. In severe cases, liver transplantation may be necessary. Early detection and ongoing medical care are vital to improving outcomes for individuals with cirrhosis.

Find out more about Cirrhosis Treatment Landscape @ Drugs for Cirrhosis Treatment- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cirrhosis Emerging Drugs Profile
• GXHPC 1: GWOXI Stem Cell Applied Technology
• LPCN 1148: Lipocine
• Belapectin: Galectin Therapeutics

Cirrhosis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Cirrhosis. The Cirrhosis companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. phase II/III include, Galectin Therapeutics.

Learn more about the emerging Cirrhosis Pipeline Therapies @ Cirrhosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Cirrhosis Pipeline Report
• Coverage- Global
• Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cirrhosis Companies- GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
• Cirrhosis Pipeline Therapies- NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.

Dive deep into rich insights for new drugs for Cirrhosis Treatment, Visit @ Cirrhosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cirrhosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase II/III)
8. Belapectin: Galectin Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GXHPC 1: GWOXI Stem Cell Applied Technology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cirrhosis Key Companies
21. Cirrhosis Key Products
22. Cirrhosis- Unmet Needs
23. Cirrhosis- Market Drivers and Barriers
24. Cirrhosis- Future Perspectives and Conclusion
25. Cirrhosis Analyst Views
26. Cirrhosis Key Companies
27. Appendix

Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.